{{infobox disease | name	Glaucoma | Image Acute angle closure glaucoma.JPG | Caption Acute angle closure glaucoma of the right eye. Note the mid sized pupil, which was nonreactive to light, and injection of the conjunctiva. | DiseasesDB 5226 | ICD10 - | ICD9 | ICDO | OMIM | MedlinePlus | eMedicineSubj oph | eMedicineTopic 578 | MeshID D005901 }}

Glaucoma is an eye disease in which the optic nerve is damaged in a characteristic pattern. This can permanently damage vision in the affected eye(s) and lead to blindness if left untreated. It is normally associated with increased fluid pressure in the eye (aqueous humour). The term 'ocular hypertension' is used for people with consistently raised intraocular pressure (IOP) without any associated optic nerve damage. Conversely, the term 'normal tension' or 'low tension' glaucoma is used for those with optic nerve damage and associated visual field loss but normal or low IOP.

The nerve damage involves loss of retinal ganglion cells in a characteristic pattern. There are many different subtypes of glaucoma, but they can all be considered to be a type of optic neuropathy. Raised intraocular pressure (above ) is the most important and only modifiable risk factor for glaucoma. However, some may have high eye pressure for years and never develop damage, while others can develop nerve damage at a relatively low pressure. Untreated glaucoma can lead to permanent damage of the optic nerve and resultant visual field loss, which over time can progress to blindness.

Glaucoma can be roughly divided into two main categories, "open angle" and "closed angle" (or "angle closure") glaucoma. The angle refers to the area between the iris and cornea, through which fluid must flow to escape via the trabecular meshwork. Closed angle glaucoma can appear suddenly and is often painful; visual loss can progress quickly, but the discomfort often leads patients to seek medical attention before permanent damage occurs. Open angle, chronic glaucoma tends to progress at a slower rate and patients may not notice they have lost vision until the disease has progressed significantly.

Glaucoma has been called the "silent thief of sight" because the loss of vision often occurs gradually over a long period of time, and symptoms only occur when the disease is quite advanced. Once lost, vision can not normally be recovered and so treatment is aimed at preventing further loss. Worldwide, glaucoma is the second leading cause of blindness after cataracts. It is also the leading cause of blindness among African Americans. Glaucoma affects one in 200 people aged fifty and younger, and one in 10 over the age of eighty. If the condition is detected early enough, it is possible to arrest the development or slow the progression with medical and surgical means.

The word "glaucoma" comes from the Greek γλαύκωμα, "opacity of the crystalline lens." (Cataracts and glaucoma were not distinguished until c.1705).

Signs and symptoms

There are two main types of glaucoma: open-angle glaucoma and closed-angle glaucoma (also called angle closure glaucoma). Open-angle glaucoma accounts for 90% of glaucoma cases in the United States. It is painless and does not have acute attacks. The only signs are gradually progressive visual field loss, and optic nerve changes (increased cup-to-disc ratio on fundoscopic examination). Closed-angle glaucoma accounts for less than 10% of glaucoma cases in the United States, but as many as half of glaucoma cases in other nations (particularly Asian countries). About 10% of patients with closed angles present with acute angle closure crises characterized by sudden ocular pain, seeing halos around lights, red eye, very high intraocular pressure (>30 mmHg), nausea and vomiting, sudden decreased vision, and a fixed, mid-dilated pupil. Acute angle closure is an emergency.

Causes

There are several causes for glaucoma. Ocular hypertension (increased pressure within the eye) is the most important risk factor in most glaucomas, but in some populations, only 50% of people with primary open angle glaucoma actually have elevated ocular pressure.

Dietary

There is no clear evidence that vitamin deficiencies cause glaucoma in humans. It follows, then, that oral vitamin supplementation is not a recommended treatment for glaucoma. Caffeine increases intraocular pressure in those with glaucoma but does not appear to affect normal individuals.

Ethnicity and gender

Many East Asian groups are prone to developing angle closure glaucoma due to their shallower anterior chamber depth, with the majority of cases of glaucoma in this population consisting of some form of angle closure. Inuit also have a 20 to 40 times higher risk than Caucasians of developing primary angle closure glaucoma. Women are three times more likely than men to develop acute angle closure glaucoma due to their shallower anterior chambers. Those of African descent are three times more likely to develop primary open angle glaucoma.

Genetics

Various rare congenital/genetic eye malformations are associated with glaucoma. Occasionally, failure of the normal third trimester gestational atrophy of the hyaloid canal and the tunica vasculosa lentis is associated with other anomalies. Angle closure induced ocular hypertension and glaucomatous optic neuropathy may also occur with these anomalies. and modelled in mice. Primary open angle glaucoma (POAG) has been found to be associated with mutations in genes at several loci. Normal tension glaucoma, which comprises one third of POAG, is associated with genetic mutations. People with a family history of glaucoma have about six percent chance of developing glaucoma.

Other

Other factors can cause glaucoma, known as "secondary glaucomas," including prolonged use of steroids (steroid-induced glaucoma); conditions that severely restrict blood flow to the eye, such as severe diabetic retinopathy and central retinal vein occlusion (neovascular glaucoma); ocular trauma (angle recession glaucoma); and uveitis (uveitic glaucoma). In a large study in the UK, glaucoma patients had a 29% increased incidence of systemic hypertension compared to age and sex matched controls.

Pathophysiology

The major risk factor for most glaucomas, and focus of treatment, is increased intraocular pressure, i.e. ocular hypertension. Intraocular pressure is a function of production of liquid aqueous humor by the ciliary processes of the eye, and its drainage through the trabecular meshwork. Aqueous humor flows from the ciliary processes into the posterior chamber, bounded posteriorly by the lens and the zonules of Zinn, and anteriorly by the iris. It then flows through the pupil of the iris into the anterior chamber, bounded posteriorly by the iris and anteriorly by the cornea. From here the trabecular meshwork drains aqueous humor via Schlemm's canal into scleral plexuses and general blood circulation.

In open angle glaucoma, there is reduced flow through the trabecular meshwork; This reduced flow is due to the cellular processes which cause the breakdown of the trabecular meshwork, whose original function is to absorb the aqueous humor. Because the aqueous humor is no longer absorbed, this leads to increased resistance and thus a buildup of pressure in the eye. in angle closure glaucoma, the iridocorneal angle is completely closed because of forward displacement of the final roll and root of the iris against the cornea resulting in the inability of the aqueous fluid to flow from the posterior to the anterior chamber and then out of the trabecular network.

The inconsistent relationship of glaucomatous optic neuropathy with ocular hypertension has provoked hypotheses and studies on anatomic structure, eye development, nerve compression trauma, optic nerve blood flow, excitatory neurotransmitter, trophic factor, retinal ganglion cell/axon degeneration, glial support cell, immune system, aging mechanisms of neuron loss, and severing of the nerve fibers at the scleral edge.

Diagnosis

Screening for glaucoma is usually performed as part of a standard eye examination performed by optometrists, orthoptists and ophthalmologists. Testing for glaucoma should include measurements of the intraocular pressure via tonometry, changes in size or shape of the eye, anterior chamber angle examination or gonioscopy, and examination of the optic nerve to look for any visible damage to it, or change in the cup-to-disc ratio and also rim appearance and vascular change. A formal visual field test should be performed. The retinal nerve fiber layer can be assessed with imaging techniques such as optical coherence tomography (OCT), scanning laser polarimetry (GDx), and/or scanning laser ophthalmoscopy, also known as Heidelberg retina tomography (HRT3).

Owing to the sensitivity of all methods of tonometry to corneal thickness, methods such as Goldmann tonometry should be augmented with pachymetry to measure central corneal thickness (CCT). A thicker-than-average cornea can result in a pressure reading higher than the 'true' pressure, whereas a thinner-than-average cornea can produce a pressure reading lower than the 'true' pressure.

Because pressure measurement error can be caused by more than just CCT (i.e., corneal hydration, elastic properties, etc.), it is impossible to 'adjust' pressure measurements based only on CCT measurements. The Frequency Doubling Illusion can also be used to detect glaucoma with the use of a frequency doubling technology (FDT) perimeter.

Examination for glaucoma also could be assessed with more attention given to sex, race, history of drug use, refraction, inheritance and family history.

+ Glaucoma Tests
!! What Test Examines !! How Examination is Accomplished
Tonometry	Inner Eye Pressure	The eye is numbed via eye drops. The examiner then uses a tonometer to measure the inner pressure of the eye through pressure applied by a warm puff of air or a tiny tool.
Ophthalmoscopy (Dilated Eye Exam)	Shape and Color of the Optic Nerve
Perimetry (Visual Field Test)	Complete Field of Vision
Gonioscopy	Angle in the Eye Where the Iris Meets the Cornea
Pachymetry	Thickness of the Cornea
GDx	Nerve Fiber Analysis	Thickness of Nerve Fiber Layer

Screening

There are no national screening programs for glaucoma in the US. There is in the UK. Those at risk are advised to have a dilated eye examination at least once a year.

Management

The modern goals of glaucoma management are to avoid glaucomatous damage and nerve damage, and preserve visual field and total quality of life for patients with minimal side effects. This requires appropriate diagnostic techniques and follow-up examinations and judicious selection of treatments for the individual patient. Although intraocular pressure is only one of the major risk factors for glaucoma, lowering it via various pharmaceuticals and/or surgical techniques is currently the mainstay of glaucoma treatment.

Vascular flow and neurodegenerative theories of glaucomatous optic neuropathy have prompted studies on various neuroprotective therapeutic strategies, including nutritional compounds, some of which may be regarded by clinicians as safe for use now, while others are on trial.

Balance and postural control

Because of the important role of the visual system in balance and maintaining posture in human beings, glaucoma patients should consider themselves at greater risk of falls, and would be advised to take the neccessary precautions in order to help prevent any accidents. In addition, since the peripheral visual system has such a high contribution to this intrinsic balancing mechanism, the severity of glaucoma and degree of visual field obstruction should also be considered. Because of the relationship of glaucoma with age, other associated factors affecting balance (i.e. impaired proprioception) may also be present, further increasing the risk of falls. Of interesting note, one cohort of open angle glaucoma patients had their ability to maintain posture measured (via measurements of sway) in binocular (two-eyed), monocular (one-eyed, using both affected and unaffected eyes) conditions, as well as with their eyes closed. These patients had increased sway (worse balance) in their one-eyed conditions compared to the two-eyed conditions, and reduced sway (better balance) when using one eye then when their eyes were closed, but there weren't significant differences between the two monocular conditions, with the unaffected eye having only slightly (but not significantly) reduced sway then when using their affected eye. All patients in each condition displayed increased compared to their age-matched controls.

Medication

Intraocular pressure can be lowered with medication, usually eye drops. Several different classes of medications are used to treat glaucoma, with several different medications in each class.

Each of these medicines may have local and systemic side effects. Adherence to medication protocol can be confusing and expensive; if side effects occur, the patient must be willing either to tolerate these, or to communicate with the treating physician to improve the drug regimen. Initially, glaucoma drops may reasonably be started in either one or in both eyes.

Poor compliance with medications and follow-up visits is a major reason for vision loss in glaucoma patients. A 2003 study of patients in an HMO found that half failed to fill their prescriptions the first time, and one-fourth failed to refill their prescriptions a second time. Patient education and communication must be ongoing to sustain successful treatment plans for this lifelong disease with no early symptoms.

The possible neuroprotective effects of various topical and systemic medications are also being investigated.

Prostaglandin analogs, such as latanoprost (Xalatan), bimatoprost (Lumigan) and travoprost (Travatan), increase uveoscleral outflow of aqueous humor. Bimatoprost also increases trabecular outflow.

Topical beta-adrenergic receptor antagonists, such as timolol, levobunolol (Betagan), and betaxolol, decrease aqueous humor production by the ciliary body.

Alpha2-adrenergic agonists, such as brimonidine (Alphagan) and apraclonidine, work by a dual mechanism, decreasing aqueous humor production and increasing uveoscleral outflow.

Less-selective alpha agonists, such as epinephrine, decrease aqueous humor production through vasoconstriction of ciliary body blood vessels, useful only in open angle glaucoma. Epinephrine's mydriatic effect, however, renders it unsuitable for closed angle glaucoma due to further narrowing of the uveoscleral outflow (i.e. further closure of trabecular meshwork, which is responsible for absorption of aqueous humor).

Miotic agents (parasympathomimetics), such as pilocarpine, work by contraction of the ciliary muscle, tightening the trabecular meshwork and allowing increased outflow of the aqueous humour. Echothiophate, an acetylcholinesterase inhibitor, is used in chronic glaucoma.

Carbonic anhydrase inhibitors, such as dorzolamide (Trusopt), brinzolamide (Azopt), and acetazolamide (Diamox), lower secretion of aqueous humor by inhibiting carbonic anhydrase in the ciliary body.

Physostigmine is also used to treat glaucoma.

Marijuana was found, in the early 1970s, to reduce pressure in the eyes, though how the cannabinoids in marijuana produce this effect remains unknown.

Surgery

Both laser and conventional surgeries are performed to treat glaucoma.

Surgery is the primary therapy for those with congenital glaucoma.

Generally, these operations are a temporary solution, as there is not yet a cure for glaucoma.

Canaloplasty

Canaloplasty is a nonpenetrating procedure using microcatheter technology. To perform a canaloplasty, an incision is made into the eye to gain access to Schlemm's canal in a similar fashion to a viscocanalostomy. A microcatheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material called viscoelastic. The catheter is then removed and a suture is placed within the canal and tightened.

By opening the canal, the pressure inside the eye may be relieved, although the reason is unclear, since the canal (of Schlemm) does not have any significant fluid resistance in glaucoma or healthy eyes. Long-term results are not available.

Laser surgery

Laser trabeculoplasty may be used to treat open angle glaucoma. It is a temporary solution, not a cure. An 50 μm argon laser spot is aimed at the trabecular meshwork to stimulate opening of the mesh to allow more outflow of aqueous fluid. Usually, half of the angle is treated at a time. Traditional laser trabeculoplasty uses a thermal argon laser in a procedure called argon laser trabeculoplasty (ALT).

A newer type of laser trabeculoplasty uses a "cold" (nonthermal) laser to stimulate drainage in the trabecular meshwork. This newer procedure, selective laser trabeculoplasty (SLT) uses a 532 nm frequency-doubled, Q-switched Nd:YAG laser, which selectively targets melanin pigment in the trabecular meshwork cells. Studies show SLT is as effective as ALT at lowering eye pressure. In addition, SLT may be repeated three to four times, whereas ALT can usually be repeated only once.

Nd:YAG laser peripheral iridotomy (LPI) may be used in patients susceptible to or affected by angle closure glaucoma or pigment dispersion syndrome. During laser iridotomy, laser energy is used to make a small, full-thickness opening in the iris to equalize the pressure between the front and back of the iris, thus correcting any abnormal bulging of the iris. In people with narrow angles, this can uncover the trabecular meshwork. In some cases of intermittent or short-term angle closure, this may lower the eye pressure. Laser iridotomy reduces the risk of developing an attack of acute angle closure. In most cases, it also reduces the risk of developing chronic angle closure or of adhesions of the iris to the trabecular meshwork.

Diode laser cycloablation lowers IOP by reducing aqueous secretion by destroying secretory ciliary epithelium.

Trabeculectomy

The most common conventional surgery performed for glaucoma is the trabeculectomy. Here, a partial thickness flap is made in the scleral wall of the eye, and a window opening is made under the flap to remove a portion of the trabecular meshwork. The scleral flap is then sutured loosely back in place to allow fluid to flow out of the eye through this opening, resulting in lowered intraocular pressure and the formation of a bleb or fluid bubble on the surface of the eye. Scarring can occur around or over the flap opening, causing it to become less effective or lose effectiveness altogether. Traditionally, chemotherapeutic adjuvants, such as mitomycin C (MMC, 0.5-0.2 mg/ml) or 5-fluorouracil (5-FU, 50 mg/ml), are applied with soaked sponges on wound bed to prevent filtering blebs from scarring by inhibiting fibroblast proliferation. Contemporary alternatives include the sole or combinative implementation of non-chemotherapeutic adjuvants, such as collagen matrix implant or other biodegradable spacers, to prevent super scarring by randomization and modulation of fibroblast proliferation in addition to the mechanical prevention of wound contraction and adhesion.

Glaucoma drainage implants

Several different glaucoma drainage implants include the original Molteno implant (1966), the Baerveldt tube shunt, or the valved implants, such as the Ahmed glaucoma valve implant or the ExPress Mini Shunt and the later generation pressure ridge Molteno implants. These are indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy). The flow tube is inserted into the anterior chamber of the eye, and the plate is implanted underneath the conjunctiva to allow flow of aqueous fluid out of the eye into a chamber called a bleb.

The first-generation Molteno and other nonvalved implants sometimes require the ligation of the tube until the bleb formed is mildly fibrosed and water-tight. This is done to reduce postoperative hypotony—sudden drops in postoperative intraocular pressure (IOP).

Valved implants, such as the Ahmed glaucoma valve, attempt to control postoperative hypotony by using a mechanical valve.

The ongoing scarring over the conjunctival dissipation segment of the shunt may become too thick for the aqueous humor to filter through. This may require preventive measures using antifibrotic medications, such as 5-fluorouracil or mitomycin-C (during the procedure), or other non-antifibrotic medication methods, such as collagen matrix implant, biodegradable spacer, or additional surgery. And for glaucomatous painful blind eye and some cases of glaucoma, cyclocryotherapy for ciliary body ablation could be considered to be performed.

Veterinary implant

TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR-ClarifEYE. The implant consists of a new biomaterial, the STAR BioMaterial, which consists of silicone with a very precise homogenous pore size, a property which reduces fibrosis and improves tissue integration. The implant contains no valves and is placed completely within the eye without sutures. To date, it has demonstrated long-term success (> 1yr) in a pilot study in medically refractory dogs with advanced glaucoma.

Laser-assisted nonpenetrating deep sclerectomy

The most common surgical approach currently used for the treatment of glaucoma is trabeculectomy, in which the sclera is punctured to alleviate intraocular pressure.

Nonpenetrating deep sclerectomy (NPDS) surgery is a similar, but modified, procedure, in which instead of puncturing the scleral wall, a patch of the sclera is skimmed to a level, upon which, percolation of liquid from the inner eye is achieved and thus alleviating IOP, without penetrating the eye. NPDS is demonstrated to cause significantly less side effects than trabeculectomy. However, NPDS is performed manually and requires great skill to achieve a lengthy learning curve.

Laser-assisted NPDS is the performance of NPDS with the use of a CO₂ laser system. The laser-based system is self-terminating once the required scleral thickness and adequate drainage of the intraocular fluid have been achieved. This self-regulation effect is achieved as the CO₂ laser essentially stops ablating as soon as it comes in contact with the intraocular percolated liquid, which occurs as soon as the laser reaches the optimal residual intact layer thickness.

Epidemiology

thumb|Disability-adjusted life year for glaucoma per 100,000 inhabitants in 2004.

Research

Advanced Glaucoma Intervention Study (AGIS) is a large American National Eye Institute-sponsored study designed "to assess the long-range outcomes of sequences of interventions involving trabeculectomy and argon laser trabeculoplasty in eyes that have failed initial medical treatment for glaucoma". It recommends different treatments based on race.

Early Manifest Glaucoma Trial (EMGT) is another NEI study that found immediate treatment of people who have early stage glaucoma can delay progression of the disease.

Ocular Hypertension Treatment Study (OHTS), also an NEI study, found topical ocular hypotensive medication was effective in delaying or preventing onset of primary open angle glaucoma (POAG) in individuals with elevated intraocular pressure. Although this does not imply that all patients with borderline or elevated IOP should receive medication, clinicians should consider initiating treatment for individuals with ocular hypertension who are at moderate or high risk for developing POAG.

The Blue Mountains Eye Study was the first large, population-based assessment of visual impairment and common eye diseases of a representative older Australian community sample. Risk factors for glaucoma and other eye disease were determined.

;Natural compounds Natural compounds of research interest in glaucoma prevention or treatment include: fish oil and omega 3 fatty acids, alpha lipoic acid, bilberries, vitamin E, cannabinoids, carnitine, coenzyme Q10, curcurmin, ''Salvia miltiorrhiza'', dark chocolate, erythropoietin, folic acid, ''Ginkgo biloba'', ginseng, L-glutathione, grape seed extract, green tea, magnesium, melatonin, methylcobalamin, N-acetyl-L cysteine, pycnogenols, resveratrol, quercetin and salt. However, most of these compounds have not demonstrated effectiveness in clinical trials. Magnesium, ginkgo, salt and fludrocortisone, are already used by some physicians. (Note: Fludrocortisone is not a natural compound, but a steroid.)

;Cannabis Studies in the 1970s showed marijuana, when smoked or eaten, effectively lowers intraocular pressure by about 25%, as much as standard medications. In an effort to determine whether marijuana, or drugs derived from marijuana, might be effective as a glaucoma treatment, the US National Eye Institute supported research studies from 1978 to 1984. These studies demonstrated some derivatives of marijuana lowered intraocular pressure when administered orally, intravenously, or by smoking, but not when topically applied to the eye.

In 2003, the American Academy of Ophthalmology released a position statement which said "studies demonstrated that some derivatives of marijuana did result in lowering of IOP when administered orally, intravenously, or by smoking, but not when topically applied to the eye. The duration of the pressure-lowering effect is reported to be in the range of 3 to 4 hours".

However, the position paper qualified that by stating marijuana was not more effective than prescription medications, and "no scientific evidence has been found that demonstrates increased benefits and/or diminished risks of marijuana use to treat glaucoma compared with the wide variety of pharmaceutical agents now available."

The first patient in the United States federal government's Compassionate Investigational New Drug program, Robert Randall, was afflicted with glaucoma and had successfully fought charges of marijuana cultivation because it was deemed a medical necessity (''U.S. v. Randall'') in 1976.

;5-HT_2A agonists Peripherally selective 5-HT_2A agonists, such as the indazole derivative AL-34662, are currently under development and show significant promise in the treatment of glaucoma.

Implanted sensor

The world's smallest computer system, one square mm in size, has been developed by researchers at the University of Michigan, and is designed to be implanted in a person's eye as a pressure monitor to continuously track the progress of glaucoma. The processor consists of an ultra-low-power microprocessor, a pressure sensor, memory, a thin-film battery, a solar cell and a wireless radio with an antenna that can transmit data to an external reader device.

ES cell

The survey team of Dr.Yoshiki Sasai, working at the RIKEN of Center for Developmental Biology (CDB) in Japan, succeeded in making a retina cell in three dimension from embryonic stem cells, as was reported in ''Nature'' (7 April 2011). It was the first such success in the world, and Dr. Sasai said that the goal for putting it to practical use in the retinas of human for clinical applications was within 2 years.

Classification

Glaucoma has been classified into specific types:

Primary glaucoma and its variants (H40.1-H40.2)

Primary glaucoma

Primary angle-closure glaucoma, also known as primary closed-angle glaucoma, narrow-angle glaucoma, pupil-block glaucoma, acute congestive glaucoma

:*Acute angle-closure glaucoma :*Chronic angle-closure glaucoma :*Intermittent angle-closure glaucoma :*Superimposed on chronic open-angle closure glaucoma ("combined mechanism" - uncommon)

Primary open-angle glaucoma, also known as chronic open-angle glaucoma, chronic simple glaucoma, glaucoma simplex

:*High-tension glaucoma :*Low-tension glaucoma Variants of primary glaucoma

Pigmentary glaucoma

Exfoliation glaucoma, also known as pseudoexfoliative glaucoma or glaucoma capsulare

Primary angle-closure glaucoma is caused by contact between the iris and trabecular meshwork, which in turn obstructs outflow of the aqueous humor from the eye. This contact between iris and trabecular meshwork (TM) may gradually damage the function of the meshwork until it fails to keep pace with aqueous production, and the pressure rises. In over half of all cases, prolonged contact between iris and TM causes the formation of synechiae (effectively "scars").

These cause permanent obstruction of aqueous outflow. In some cases, pressure may rapidly build up in the eye, causing pain and redness (symptomatic, or so called "acute" angle-closure). In this situation, the vision may become blurred, and halos may be seen around bright lights. Accompanying symptoms may include headache and vomiting.

Diagnosis is made from physical signs and symptoms: pupils mid-dilated and unresponsive to light, cornea edematous (cloudy), reduced vision, redness, and pain. However, the majority of cases are asymptomatic. Prior to very severe loss of vision, these cases can only be identified by examination, generally by an eye care professional.

Once any symptoms have been controlled, the first line (and often definitive) treatment is laser iridotomy. This may be performed using either Nd:YAG or argon lasers, or in some cases by conventional incisional surgery. The goal of treatment is to reverse, and prevent, contact between iris and trabecular meshwork. In early to moderately advanced cases, iridotomy is successful in opening the angle in around 75% of cases. In the other 25%, laser iridoplasty, medication (pilocarpine) or incisional surgery may be required.

Primary open-angle glaucoma is when optic nerve damage results in a progressive loss of the visual field. This is associated with increased pressure in the eye. Not all people with primary open-angle glaucoma have eye pressure that is elevated beyond normal, but decreasing the eye pressure further has been shown to stop progression even in these cases.

The increased pressure is caused by trabecular blockage which is where the aqueous humor in the eye drains out. Because the microscopic passageways are blocked, the pressure builds up in the eye and causes imperceptible very gradual vision loss. Peripheral vision is affected first, but eventually the entire vision will be lost if not treated.

Diagnosis is made by looking for cupping of the optic nerve. Prostaglandin agonists work by opening uveoscleral passageways. Beta blockers, such as timolol, work by decreasing aqueous formation. Carbonic anhydrase inhibitors decrease bicarbonate formation from ciliary processes in the eye, thus decreasing formation of Aqueous humor. Parasympathetic analogs are drugs that work on the trabecular outflow by opening up the passageway and constricting the pupil. Alpha 2 agonists (brimonidine, apraclonidine) both decrease fluid production (via. inhibition of AC) and increase drainage.

Developmental glaucoma (Q15.0)

Developmental glaucoma

Primary congenital glaucoma

Infantile glaucoma

Glaucoma associated with hereditary of familial diseases

Secondary glaucoma (H40.3-H40.6)

Secondary glaucoma

Inflammatory glaucoma

:*Uveitis of all types :*Fuchs heterochromic iridocyclitis

Phacogenic glaucoma

:*Angle-closure glaucoma with mature cataract :*Phacoanaphylactic glaucoma secondary to rupture of lens capsule :*Phacolytic glaucoma due to phacotoxic meshwork blockage :*Subluxation of lens

Glaucoma secondary to intraocular hemorrhage

:*Hyphema :*Hemolytic glaucoma, also known as erythroclastic glaucoma

Traumatic glaucoma

:*Angle recession glaucoma: Traumatic recession on anterior chamber angle :*Postsurgical glaucoma ::*Aphakic pupillary block ::*Ciliary block glaucoma

Neovascular glaucoma (see below for more details)

Drug-induced glaucoma

:*Corticosteroid induced glaucoma :*Alpha-chymotrypsin glaucoma. Postoperative ocular hypertension from use of alpha chymotrypsin.

Glaucoma of miscellaneous origin

:*Associated with intraocular tumors :*Associated with retinal detachments :*Secondary to severe chemical burns of the eye :*Associated with essential iris atrophy :*Toxic glaucoma

Neovascular glaucoma, an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor blood flow to the eye are highly at risk for this condition.

Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage. Patients with such condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. A new treatment for this disease, as first reported by Kahook and colleagues, involves use of a novel group of medications known as anti-VEGF agents. These injectable medications can lead to a dramatic decrease in new vessel formation and, if injected early enough in the disease process, may lead to normalization of intraocular pressure.

Toxic glaucoma is open angle glaucoma with an unexplained significant rise of intraocular pressure following unknown pathogenesis. Intraocular pressure can sometimes reach . It characteristically manifests as ciliary body inflammation and massive trabecular oedema that sometimes extends to Schlemm's canal. This condition is differentiated from malignant glaucoma by the presence of a deep and clear anterior chamber and a lack of aqueous misdirection. Also, the corneal appearance is not as hazy. A reduction in visual acuity can occur followed neuroretinal breakdown.

Associated factors include inflammation, drugs, trauma and intraocular surgery, including cataract surgery and vitrectomy procedures. Gede Pardianto (2005) reported on four patients who had toxic glaucoma. One of them underwent phaecoemulsification with small particle nucleus drops. Some cases can be resolved with some medication, vitrectomy procedures or trabeculectomy. Valving procedures can give some relief, but further research is required.

Absolute glaucoma (H44.5)

Absolute glaucoma is the end stage of all types of glaucoma. The eye has no vision, absence of pupillary light reflex and pupillary response, and has a stony appearance. Severe pain is present in the eye. The treatment of absolute glaucoma is a destructive procedure like cyclocryoapplication, cyclophotocoagulation, or injection of 100% alcohol.

References

External links

GeneReview/NCBI/NIH/UW entry on Primary Congenital Glaucoma

Mar 2008 BBC article on diagnosis advances

''Glaucoma'', by Gary Heiting, OD and Marilyn Haddrill, ''All About Vision''

Category:Blindness Category:Glaucoma Category:Greek loanwords

ar:زرق bg:Глаукома ca:Glaucoma cs:Glaukom da:Grøn stær de:Glaukom et:Glaukoom el:Γλαύκωμα es:Glaucoma eo:Glaŭkomo eu:Glaukoma fa:آب سیاه fr:Glaucome ko:녹내장 hy:Գլաուկոմա hi:कांचबिंदु hr:Glaukom io:Glaukomo id:Glaukoma is:Gláka it:Glaucoma he:גלאוקומה lv:Glaukoma lt:Glaukoma hu:Zöld hályog ms:Glaukoma nl:Glaucoom ja:緑内障 no:Glaukom pap:Gloucoma pms:Glaucòma pl:Jaskra pt:Glaucoma ro:Glaucom ru:Глаукома simple:Glaucoma sk:Zelený zákal sl:Glavkom sr:Глауком sh:Glaukom fi:Glaukooma sv:Glaukom ta:கண் அழுத்த நோய் te:నీటి కాసులు th:ต้อหิน tr:Glokom uk:Глаукома ur:زرق vi:Glôcôm zh:青光眼